Healthcare / Medical DevicesKSE
$4770.00
+15.00 (+0.32%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $6.1B · quality 49.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
22/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$482.9B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-5.8%
↓Gross Margin
55.6%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-37.3%
FCF CAGR
-69.1%
FCF margin
5.2%
FCF / Net income
-0.07x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $118.32B · net income $-87.50B · FCF $6.11B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $118.32B | $118.32B | $102.78B | $90.08B | $479.66B |
| Net Income | $-87.50B | $-87.50B | $55.26B | $-20.50B | $307.80B |
| EBITDA | $-78.05B | $-78.05B | $81.75B | $-100.68B | $421.31B |
| EPS | -865.00 | -865.00 | 542.00 | -201.00 | 3264.00 |
| Gross Margin | 55.6% | 55.6% | 49.9% | -12.8% | 71.0% |
| Operating Margin | 14.2% | 14.2% | 11.9% | -52.2% | 61.6% |
| Net Margin | -73.9% | -73.9% | 53.8% | -22.8% | 64.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 10.15 | 10.15 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $6.11B | $6.11B | $47.43B | $-8.74B | $206.62B |
| Returns | |||||
| ROE | -5.8% | -5.8% | 3.4% | -1.3% | 19.2% |
| Valuation | |||||
| P/E | — | — | 8.87 | — | 2.67 |
| EV/EBITDA | — | — | 4.73 | — | 0.34 |
| P/B | 0.32 | 0.32 | 0.30 | 0.28 | 0.51 |
| Growth & Yield | |||||
| Revenue Growth | 15.1% | 15.1% | 14.1% | -81.2% | — |
| EPS Growth | -259.6% | -259.6% | 369.7% | -106.2% | — |
| Dividend Yield | 4.8% | 4.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+6.9%
Start / end P/E
n/dx → n/dx
EPS bridge
542.00 → -865.00
Residual
+2.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.